The Human Anti-Crimean-Congo Hemorrhagic Fever Virus (CCHFV) IgM ELISA Kit detects and quantifies CCHFV -specific IgM in human serum or plasma of vaccinated, immunized and/or infected hosts. This immunoassay is suitable for:
_ Determining immune status relative to non- immune controls;
_ Assessing efficacy of vaccines, including dosage, adjuvantcy, route of immunization and timing;
_ Qualifying and standardizing vaccine batches & protocols.
The CCHFV NP-coated plate and the anti-Human IgM HRP concentration are optimized to differentiate anti- CCHFV IgM from background (non-antibody) signal with human serum samples diluted 1:200.
The Calibrators are composed of dilutions of antibody to CCHFV NP. Values are assigned in arbitrary units.
Crimean-Congo hemorrhagic fever (CCHF) is a widespread tick-borne viral disease, a zoonosis of domestic animals and wild animals, that may affect humans. The pathogenic virus, especially common in East and West Africa, is a member of the Bunyaviridae family of RNA viruses. Clinical disease is rare in infected mammals, but is commonly severe in infected humans, with a 30% mortality rate. Outbreaks of illness are usually attributable to handling infected animals or humans. CCHF is distributed throughout Eastern Europe, the Mediterranean, northwestern China, central Asia Africa, the Middle East, and the Indian subcontinent.
The virus genome is circular, ambisense RNA in three parts - Small (S), Middle (M) and Large (L). The L segment encodes the RNA polymerase; the M segment encodes the envelope proteins (Gc and Gn); and the S segment encodes the nucleocapsid protein. The envelope protein is initially translated as a glycoprotein precursor which is then cleaved into two smaller proteins. Based on the sequence data seven genotypes have been recognized: Africa 1 (Senegal), Africa 2 (Democratic Republic of the Congo and South Africa), Africa 3 (southern and western Africa), Europe 1 (Albania, Bulgaria, Kosovo, Russia and Turkey), Europe 2 (Greece) Asia 1 (the Middle East, Iran and Pakistan) and Asia 2 (China, Kazakhstan, Tajikistan and Uzbekistan).
Vaccines: A Turkish research team led by Refik Saydam Health Institute has developed treatment- serum derived from blood of several CCHF-patients, which have been proven to be %90 effective in CCHF patients. The vaccine is pending for FDA approval.
ADI has cloned, expressed and purified CCHFV nucleoprotein (482-aa, ~55 kDa) that is being used as a candidate for newer subunit vaccine for CCHF.